Induction of growth factor expression is reduced during healing of tympanic membrane perforations in glucocorticoid-treated rats.
The participation of growth factors in wound healing of tympanic membranes (TMs) is established. To determine the possible role of these growth factors in normal healing, we examined the regulation of keratinocyte growth factor (KGF), transforming growth factor-alpha (TGF-alpha), and basic fibroblast growth factor (bFGF) messenger RNA (mRNA) expression in wounded TMs of glucocorticoid-treated rats; these rats have severe wound healing abnormalities. Induction of KGF, TGF-alpha, and bFGF mRNA expression after TM injury was significantly reduced in these rats. Moreover, we found that the average number of bromodeoxyuridine-positive cells in a glucocorticoid-treated group was significantly lower than that in controls. The data suggest that reduced expression of these genes might be partially responsible for the wound healing defects seen in these animals. These results provide a possible explanation for the beneficial effect of exogenous KGF, TGF-alpha, or bFGF in treatment of wound healing disorders of the TM.
Ishimoto
Shin-ichi
S
Department of Otolaryngology, University of Tokyo, Japan.
Ishibashi
Toshio
T
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D015139:Blotting, Southern; D001973:Bromodeoxyuridine / Q000032:analysis; D002452:Cell Count; D003907:Dexamethasone / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D015536:Down-Regulation; D016222:Fibroblast Growth Factor 2 / Q000187:drug effects / Q000235:genetics / Q000627:therapeutic use; D051523:Fibroblast Growth Factor 7; D005346:Fibroblast Growth Factors / Q000235:genetics; D005500:Follow-Up Studies; D015870:Gene Expression; D005938:Glucocorticoids / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006133:Growth Substances / Q000235:genetics* / Q000627:therapeutic use*; D007150:Immunohistochemistry; D007279:Injections, Subcutaneous; D008297:Male; D012313:RNA / Q000302:isolation & purification; D012333:RNA, Messenger / Q000302:isolation & purification; D051381:Rats; D017208:Rats, Wistar; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013194:Staining and Labeling; D013997:Time Factors; D016211:Transforming Growth Factor alpha / Q000187:drug effects / Q000235:genetics / Q000627:therapeutic use; D018058:Tympanic Membrane Perforation / Q000188:drug therapy / Q000473:pathology; D014945:Wound Healing / Q000187:drug effects
D000893:Anti-Inflammatory Agents; C496455:Fgf7 protein, rat; D005938:Glucocorticoids; D006133:Growth Substances; D012333:RNA, Messenger; D016211:Transforming Growth Factor alpha; D016222:Fibroblast Growth Factor 2; D051523:Fibroblast Growth Factor 7; D005346:Fibroblast Growth Factors; D012313:RNA; D003907:Dexamethasone; D001973:Bromodeoxyuridine